Get the Stockscreener App
8.41
13.04%
0.97
Xencor Inc stock is traded at $8.41, with a volume of 1.07M.
It is up +13.04% in the last 24 hours and down -8.59% over the past month.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.
See More
Previous Close:
$7.44
Open:
$7.51
24h Volume:
1.07M
Relative Volume:
1.43
Market Cap:
$599.83M
Revenue:
$133.62M
Net Income/Loss:
$-177.37M
P/E Ratio:
-2.91
EPS:
-2.89
Net Cash Flow:
$23.50M
1W Performance:
+9.51%
1M Performance:
-8.59%
6M Performance:
-46.57%
1Y Performance:
-49.55%
1-Day Range:
$7.50
$8.80
1-Week Range:
$7.13
$8.80
52-Week Range:
$6.92
$27.24
Xencor Inc Stock (XNCR) Company Profile
Name
Xencor Inc
Sector
Industry
Phone
626-305-5900
Address
465 N. HALSTEAD ST., PASADENA, CA
Compare XNCR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XNCR
Xencor Inc
|
8.41 | 557.03M | 133.62M | -177.37M | 23.50M | -2.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Xencor Inc Stock (XNCR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-21-25 | Initiated | William Blair | Outperform |
| Dec-12-24 | Initiated | Wells Fargo | Overweight |
| Dec-02-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Apr-16-24 | Reiterated | BTIG Research | Buy |
| Feb-28-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| May-19-23 | Initiated | BofA Securities | Buy |
| Dec-06-22 | Initiated | Cowen | Outperform |
| Oct-13-22 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-21-22 | Initiated | JP Morgan | Overweight |
| Jul-06-22 | Resumed | Canaccord Genuity | Buy |
| Feb-11-22 | Initiated | BMO Capital Markets | Outperform |
| Jan-21-22 | Initiated | SMBC Nikko | Outperform |
| Dec-15-21 | Initiated | H.C. Wainwright | Buy |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Feb-24-21 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Mar-04-20 | Initiated | Barclays | Underweight |
| Feb-25-20 | Upgrade | Guggenheim | Neutral → Buy |
| Jan-30-20 | Initiated | RBC Capital Mkts | Outperform |
| Nov-20-19 | Resumed | Guggenheim | Neutral |
| Aug-07-19 | Downgrade | Guggenheim | Buy → Neutral |
| Aug-07-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jun-13-19 | Initiated | Mizuho | Buy |
| Apr-12-19 | Initiated | Guggenheim | Buy |
| Mar-27-19 | Initiated | Berenberg | Buy |
| Mar-15-19 | Initiated | Raymond James | Outperform |
| Sep-10-18 | Resumed | BTIG Research | Buy |
| Mar-28-18 | Resumed | Leerink Partners | Outperform |
| Mar-02-17 | Initiated | Instinet | Neutral |
| Mar-02-17 | Reiterated | Wedbush | Outperform |
| Oct-04-16 | Initiated | Piper Jaffray | Overweight |
| Dec-22-15 | Initiated | Canaccord Genuity | Buy |
| Aug-05-15 | Reiterated | MLV & Co | Buy |
| Feb-12-15 | Reiterated | Oppenheimer | Outperform |
| Jan-28-15 | Reiterated | MLV & Co | Buy |
| Jul-11-14 | Initiated | Oppenheimer | Outperform |
View All
Xencor Inc Stock (XNCR) Latest News
Xencor Inc. Facing Inflection Point in Trend AnalysisWeekly Risk Report & Consistent Return Strategy Ideas - thegnnews.com
Price Clustering Detected in Xencor Inc. Stock2025 Winners & Losers & Technical Confirmation Trade Alerts - kangso.co.kr
What are the future prospects of Xencor Inc.July 2025 Outlook & Daily Profit Maximizing Tips - mustnews.co.kr
Is it time to cut losses on Xencor Inc.Gold Moves & AI Forecast for Swing Trade Picks - Newser
Advanced analytics toolkit walkthrough for Xencor Inc.Market Performance Recap & Growth Focused Stock Pick Reports - Newser
Using fundamentals and technicals on Xencor Inc.Market Performance Recap & Breakout Confirmation Alerts - Newser
What earnings revisions data tells us about Xencor Inc.2025 Market WrapUp & Accurate Trade Setup Notifications - Newser
Using data tools to time your Xencor Inc. exitRisk Management & Technical Pattern Alert System - Newser
Heatmap analysis for Xencor Inc. and competitorsJuly 2025 Market Mood & Risk Controlled Daily Trade Plans - Newser
Regression analysis insights on Xencor Inc. performanceJuly 2025 WrapUp & Fast Gain Swing Alerts - Newser
How Xencor Inc. stock performs during market volatilityWeekly Profit Recap & AI Driven Price Predictions - Newser
Xencor Inc. stock trend outlook and recovery pathQuarterly Profit Review & Short-Term High Return Ideas - Newser
What’s the analyst consensus on Xencor Inc.July 2025 Opening Moves & Capital Efficient Trading Techniques - thegnnews.com
Xencor’s SWOT analysis: biotech stock faces pivotal clinical trials By Investing.com - Investing.com Nigeria
Will Xencor Inc. Sustain Its Chart Breakout2025 Price Action Summary & Long-Term Capital Growth Strategies - metal.it
Xencor’s SWOT analysis: biotech stock faces pivotal clinical trials - Investing.com
Custom Dashboard Highlights Xencor Inc. Price MomentumJuly 2025 Closing Moves & Daily Technical Forecast Reports - beatles.ru
Wedbush Estimates Xencor’s Q3 Earnings (NASDAQ:XNCR) - Defense World
William Blair Analysts Boost Earnings Estimates for Xencor - Defense World
Using portfolio simulators with Xencor Inc. includedEntry Confirmation Using Short-Term Forecasting - Newser
Wedbush Cuts Xencor (NASDAQ:XNCR) Price Target to $26.00 - Defense World
Xencor, Inc. (NASDAQ:XNCR) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates - uk.finance.yahoo.com
Xencor price target lowered to $26 from $31 at Wedbush - Yahoo Finance
Xencor’s XmAb541 Study Completion: A Potential Game-Changer in Oncology - TipRanks
Xencor’s XmAb808 Study: A New Frontier in Cancer Treatment - TipRanks
Xencor’s XmAb541 Study: A Promising Step in Cancer Treatment - TipRanks
Xencor’s XmAb942 Shows Promising Efficacy and Strategic Advancements, Earning a Buy Rating - TipRanks
Wedbush Cuts Price Target on Xencor to $26 From $31, Keeps Outperform Rating - MarketScreener
Xencor’s Strategic Advances and Promising Pipeline Drive Buy Rating - TipRanks
Xencor 2025 Q2 Earnings Strong Revenue Growth, 55.2% Reduction in Net Loss - AInvest
Xencor Inc earnings beat by $0.31, revenue topped estimates - Investing.com India
Xencor Reports Second Quarter 2025 Financial Results - BioSpace
Xencor, Inc. Reports Revenue Growth Amidst Continued Losses - TipRanks
Xencor: Q2 Earnings Snapshot - San Antonio Express-News
Xencor Q2 Earnings: Losses Reported but Revenue Surpasses ExpectationsNews and Statistics - IndexBox
Xencor (XNCR) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Xencor (XNCR) Q2 Revenue Jumps 82% - sharewise.com
Xencor, Inc.'s (NASDAQ:XNCR) Price Is Right But Growth Is Lacking - simplywall.st
Published on: 2025-08-06 00:25:22 - Newser
What’s the recovery path for long term holders of Xencor Inc.Free Pattern Detection for Entry Confirmation - Newser
Xencor Inc. Flashes Rebound Signal in Oversold ConditionConfirmed Setup With Expert Accuracy Supported - metal.it
How does Xencor Inc. generate profit in a changing economyRapid market gains - Jammu Links News
What is the dividend policy of Xencor Inc. stockMaximize portfolio value with expert tips - Jammu Links News
When is Xencor Inc. stock expected to show significant growthSuperior capital gains - Jammu Links News
What is Xencor Inc. company’s growth strategyLightning-fast growth - Jammu Links News
Is it the right time to buy Xencor Inc. stockSky-high return potential - Jammu Links News
How many analysts rate Xencor Inc. as a “Buy”Overwhelming profit margins - Jammu Links News
What catalysts could drive Xencor Inc. stock higher in 2025Strong return on investment - Jammu Links News
How does Xencor Inc. compare to its industry peersConsistent triple returns - Jammu Links News
Should I hold or sell Xencor Inc. stock in 2025Triple-digit growth rates - Jammu Links News
Is Xencor Inc. a growth stock or a value stockFree Expert Stock Watchlist - Jammu Links News
Xencor Inc Stock (XNCR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Xencor Inc Stock (XNCR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| GUSTAFSON KURT A | Director |
Jun 16 '25 |
Sale |
9.22 |
2,993 |
27,595 |
20,183 |
| GORMAN KEVIN CHARLES | Director |
Jun 16 '25 |
Sale |
9.22 |
3,173 |
29,255 |
18,905 |
| Feigal Ellen | Director |
Jun 16 '25 |
Sale |
9.22 |
2,993 |
27,595 |
19,183 |
| RANIERI RICHARD J | Director |
Jun 16 '25 |
Sale |
9.22 |
2,993 |
27,595 |
19,183 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):